How is the Design Therapeutics Inc today?

The Design Therapeutics Inc today is trading in the green, up by 4.46% at 3.51.

How has Design Therapeutics Inc performed historically?

The Design Therapeutics Inc is currently trading up 4.46% on an intraday basis in the past week the index fell -0.28%. The index has been down -13.97% in the past quarter and fell -22.17% in the past year. You can view this in the overview section.

What is Design Therapeutics Inc Annual Net Profit?

Design Therapeutics Inc Annual Net Profit rose 25.84% in the last year to $49.59 M. Its sector's average net profit growth for the last fiscal year was -9.67%.

What is Design Therapeutics Inc Price to Earning Ratio?

Design Therapeutics Inc Price to Earning Ratio is -3.55, which is negative.

What is Design Therapeutics Inc Stock Price?

Design Therapeutics Inc Stock Price fell 22.17% and underperformed its sector by 32.23% in the past year.

What is Design Therapeutics Inc Quarterly Net profit?

Design Therapeutics Inc Quarterly Net profit fell 59.52% YoY to $17.72 M. Its sector's average net profit growth YoY for the quarter was -211.72%.

What is Design Therapeutics Inc Debt to Equity Ratio?

Design Therapeutics Inc Debt to Equity Ratio of 0.01 is less than 1 and healthy. This implies that its assets are financed mainly through equity.

What is Design Therapeutics Inc Return on Equity(ROE)?

Design Therapeutics Inc Return on Equity(ROE) for the last financial year was -19.08%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.

What is Design Therapeutics Inc Mutual Fund Holding?

Design Therapeutics Inc Mutual Fund Holding decreased by 0.23% in the last quarter to 15.44.

What is Design Therapeutics Inc Institutional Holding?

Design Therapeutics Inc Institutional Holding decreased by 0.27% in the last quarter to 54.31.

Design Therapeutics Inc XNAS: DSGN

Design Therapeutics Inc Live Share Price Today, Share Analysis and Chart

Name: Design Therapeutics Inc: Is Infosys Ltd. worth buying?
Item: Design Therapeutics Inc
Rating: 0.86600
Author: Trendlyne DVM scores

about

Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modify...

3.51 0.15 (4.46%)

54.83% Fall from 52W High

70,352 XNAS Volume

XNAS 16 May, 2025 4:14 PM (EDT)

Board Meeting

The next board meeting for Design Therapeutics Inc is on 20 May 2025 for the purpose of 2025 RBC Capital Markets Healthcare Conference See details

Not Eligible

Expensive Valuation

12.0 / 100

Technically Bearish

22.6 / 100

No estimates available

Design Therapeutics Inc Live Price Chart

Switch to TradingView

Loading Fundamental data..

Loading data..

Design Therapeutics Inc Live Share Price Today, Share Analysis and Chart

Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modify...

54.83% Fall from 52W High

SWOT Analysis

Design Therapeutics Inc Live Price Chart

Design Therapeutics Inc FAQ

How is Design Therapeutics Inc today?

Design Therapeutics Inc today is trading in the green, and is up by 4.46% at 3.51.

How has Design Therapeutics Inc performed historically?

Design Therapeutics Inc is currently trading up 4.46% on an intraday basis. In the past week the stock fell -0.28%. stock has been down -13.97% in the past quarter and fell -22.17% in the past year. You can view this in the overview section.